These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 23375565)
1. New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Yang T; Hong S; O'Malley T; Sperling RA; Walsh DM; Selkoe DJ Alzheimers Dement; 2013 Mar; 9(2):99-112. PubMed ID: 23375565 [TBL] [Abstract][Full Text] [Related]
3. Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Bruggink KA; Jongbloed W; Biemans EA; Veerhuis R; Claassen JA; Kuiperij HB; Verbeek MM Anal Biochem; 2013 Feb; 433(2):112-20. PubMed ID: 23022042 [TBL] [Abstract][Full Text] [Related]
4. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease. Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249 [TBL] [Abstract][Full Text] [Related]
5. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Xia W; Yang T; Shankar G; Smith IM; Shen Y; Walsh DM; Selkoe DJ Arch Neurol; 2009 Feb; 66(2):190-9. PubMed ID: 19204155 [TBL] [Abstract][Full Text] [Related]
6. Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Jensen M; Hartmann T; Engvall B; Wang R; Uljon SN; Sennvik K; Näslund J; Muehlhauser F; Nordstedt C; Beyreuther K; Lannfelt L Mol Med; 2000 Apr; 6(4):291-302. PubMed ID: 10949910 [TBL] [Abstract][Full Text] [Related]
8. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805 [TBL] [Abstract][Full Text] [Related]
9. Detection of Amyloid-beta aggregates in body fluids: a suitable method for early diagnosis of Alzheimer's disease? Funke SA; Birkmann E; Willbold D Curr Alzheimer Res; 2009 Jun; 6(3):285-9. PubMed ID: 19519310 [TBL] [Abstract][Full Text] [Related]
10. Methods for the Specific Detection and Quantitation of Amyloid-β Oligomers in Cerebrospinal Fluid. Schuster J; Funke SA J Alzheimers Dis; 2016 May; 53(1):53-67. PubMed ID: 27163804 [TBL] [Abstract][Full Text] [Related]
12. Reappraisal of Aβ40 and Aβ42 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer's Disease. Fiorini M; Bongianni M; Benedetti MD; Monaco S; Zanusso G J Alzheimers Dis; 2018; 66(1):219-227. PubMed ID: 30282368 [TBL] [Abstract][Full Text] [Related]
13. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. Tucker S; Möller C; Tegerstedt K; Lord A; Laudon H; Sjödahl J; Söderberg L; Spens E; Sahlin C; Waara ER; Satlin A; Gellerfors P; Osswald G; Lannfelt L J Alzheimers Dis; 2015; 43(2):575-88. PubMed ID: 25096615 [TBL] [Abstract][Full Text] [Related]
14. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. Santos AN; Ewers M; Minthon L; Simm A; Silber RE; Blennow K; Prvulovic D; Hansson O; Hampel H J Alzheimers Dis; 2012; 29(1):171-6. PubMed ID: 22214781 [TBL] [Abstract][Full Text] [Related]
15. Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics. Rosseels J; Van den Brande J; Violet M; Jacobs D; Grognet P; Lopez J; Huvent I; Caldara M; Swinnen E; Papegaey A; Caillierez R; Buée-Scherrer V; Engelborghs S; Lippens G; Colin M; Buée L; Galas MC; Vanmechelen E; Winderickx J J Biol Chem; 2015 Feb; 290(7):4059-74. PubMed ID: 25540200 [TBL] [Abstract][Full Text] [Related]